CClinicalTrials.gg
Status unknownNCT04359485Updated Apr 24, 2020

New Score for Pseudo- Acanthosis Nigricans

An interventional study of Glycolic acids peel 70% and Saline in Pseudo Acanthosis Nigricans, sponsored by Kasr El Aini Hospital. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by Kasr El Aini Hospital · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2019, registered Apr 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Each side of the neck pseudo acanthosis nigricans was randomized in to either receiving glycolic acid peel or saline. Evaluation was done at baseline and after 3 sessions 2 weeks apart by percentage involvement and by ANASI score

02

Conditions studied

  • Pseudo Acanthosis Nigricans
03

In context

Lead sponsor

Kasr El Aini Hospital is the lead sponsor of 273 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • mild to moderate severity
  • age > 18 years old

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating patients,
  • patients with systemic diseases as connective tissue disease, diabetes,
  • skin infection
  • use of immunosuppressive drugs
  • Susceptibility for post peel hazards as hyperpigmentation
  • scarring and keloidal tendency
05

Study design

Phase
Not applicable
Primary purpose
Other
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    glycolic acid peel

    Procedure: Glycolic acids peel 70%

  • Placebo comparator
    Saline

    Other: Saline

Interventions

  • ProcedureGlycolic acids peel 70%

    Glycolic acid peel 70% applied in 3 coats medium depth

  • OtherSaline

    Sodium chloride

06

What researchers measure

Primary outcomes

  1. Percentage involvement

    Degree of severity expressed as a percentage

    Time frame: 6 months to 1 year

  2. Acanthosis Nigricans Area and Severity Index score

    New Score calculating severity and area as a number minimum value is 0 and maximum value is 40 the higher the number of the score the worse the affection

    Time frame: 6 months to 1 year

07

Study locations

1 site
  • Kasr El Ainy university hospital, Faulty of medicine,Cairo university
    Cairo, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04359485
Lead sponsor
Kasr El Aini Hospital
Responsible party
Rana F Hilal, MD (Principal Investigator, Kasr El Aini Hospital) — Principal investigator
First posted
Apr 24, 2020
Start date
Aug 1, 2019
Primary completion
Nov 1, 2019
Completion
Jun 2020 (estimated)
Last update
Apr 24, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion